- Conditions
- Psoriasis, Psoriatic Arthritis
- Interventions
- Apremilast, Etanercept, Placebo tablet, Placebo injection
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 167
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sciatica
- Interventions
- epidural injection of etanercept, placebo (control procedure)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Vitiligo
- Interventions
- Etanercept
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Healthy, Inflammation
- Interventions
- etanercept (Enbrel)
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- Not listed
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
- Interventions
- Neihulizumab Treatment, Conventional Treatment
- Biological
- Lead sponsor
- AbGenomics B.V Taiwan Branch
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- etanercept
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- HIV Infections
- Interventions
- etanercept
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Gout Attack
- Interventions
- Etanercept, Triamcinolone Acetonide
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Placebo, Etanercept
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- tofacitinib, adalimumab, etanercept
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 4,372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more
- Conditions
- CRPS, Chronic Regional Pain Syndrome
- Interventions
- Etanercept, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 10 Years to 17 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Psoriasis
- Interventions
- Etanercept
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
- Conditions
- Psoriasis
- Interventions
- Enstilar 0.005%-0.064% Topical Foam
- Drug
- Lead sponsor
- Psoriasis Treatment Center of Central New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- East Windsor, New Jersey
- Conditions
- Bronchitis
- Interventions
- Etanercept inhibition of ozone-induced airway hyper-responsiveness.
- Drug
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Psoriasis
- Interventions
- Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept
- Procedure · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- End Stage Renal Disease
- Interventions
- Etanercept, Placebo
- Drug
- Lead sponsor
- Kaysen, George A., M.D., Ph.D.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Tumors
- Interventions
- Etanercept, Docetaxel, Dexamethasone
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Etanercept
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 12
- States / cities
- Pensacola, Florida • Chicago, Illinois • Mineola, New York + 4 more
- Conditions
- Alzheimer's Disease
- Interventions
- etanercept given by perispinal administration
- Drug
- Lead sponsor
- Tobinick, Edward Lewis, M.D.
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pneumonia, Idiopathic Pneumonia Syndrome
- Interventions
- Etanercept, Placebo plus corticosteroid
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 12
- States / cities
- Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more
- Conditions
- Chronic Severe Plaque-type Psoriasis
- Interventions
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Lichen Planus
- Interventions
- Etanercept, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 12
- States / cities
- Stanford, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
- Procedure · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 9
- States / cities
- San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
- Conditions
- Wegener's Granulomatosis
- Interventions
- Etanercept
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 11 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 8
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more